234 related articles for article (PubMed ID: 33838339)
1. Omalizumab response in patients with asthma by number and type of allergen.
Soong W; Yoo B; Pazwash H; Holweg CTJ; Casale TB
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):223-231. PubMed ID: 33838339
[TBL] [Abstract][Full Text] [Related]
2. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457
[TBL] [Abstract][Full Text] [Related]
3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
4. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
6. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
7. Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a
Li J; Wang C; Liu C; Kang J; Kong L; Huang Y; Liu S; Huang M; Wang L; Fogel R; Jaumont X; Yang J; Zhong N
World Allergy Organ J; 2020 Dec; 13(12):100469. PubMed ID: 34611470
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
10. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
[TBL] [Abstract][Full Text] [Related]
13. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
15. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
Massanari M; Kianifard F; Zeldin RK; Geba GP
Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
[TBL] [Abstract][Full Text] [Related]
17. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma.
Janson SL; Solari PG; Trzaskoma B; Chen H; Haselkorn T; Zazzali JL
Ann Allergy Asthma Immunol; 2015 Jun; 114(6):516-21. PubMed ID: 26021894
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
20. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]